{"filing":{"accession_number":"0001193125-26-330541","cik":"0001285550","ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"clpt-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/clpt-20260803.htm"},"events":[{"id":23344,"run_id":21106,"accession_number":"0001193125-26-330541","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ClearPoint Neuro issued a press release on August 3, 2026 announcing Q2 2026 financial results, reporting revenue of $10.9 million (18% growth), gross margin of 62%, operating expenses of $17.0 million, and revising full-year 2026 revenue guidance to $48.0–$52.0 million.","company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23545,"accession_number":"0001193125-26-330541","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ClearPoint Neuro issued a press release on August 3, 2026 announcing financial results for the second fiscal quarter ended June 30, 2026. The disclosure includes Q2 2026 revenue of $10.9 million (18% growth), segment-level revenue details, gross margin of 62%, operating expenses of $17.0 million, and revised 2026 full-year revenue guidance of $48.0–$52.0 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:19.181584+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23546,"accession_number":"0001193125-26-330541","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ClearPoint Neuro disclosed second quarter 2026 financial results on August 3, 2026, reporting Q2 revenue of $10.9 million (18% growth) and providing revised 2026 full-year revenue guidance of $48.0–$52.0 million. The press release (Exhibit 99.1) contains detailed financial metrics, segment performance analysis, gross margin, operating expenses, and cash position, along with management commentary on business outlook and strategic priorities. This is a standard quarterly earnings release material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:19.181584+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23545,"accession_number":"0001193125-26-330541","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ClearPoint Neuro issued a press release on August 3, 2026 announcing financial results for the second fiscal quarter ended June 30, 2026. The disclosure includes Q2 2026 revenue of $10.9 million (18% growth), segment-level revenue details, gross margin of 62%, operating expenses of $17.0 million, and revised 2026 full-year revenue guidance of $48.0–$52.0 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:19.181584+00:00","company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","filing_date":"2026-08-03"},{"id":23546,"accession_number":"0001193125-26-330541","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ClearPoint Neuro disclosed second quarter 2026 financial results on August 3, 2026, reporting Q2 revenue of $10.9 million (18% growth) and providing revised 2026 full-year revenue guidance of $48.0–$52.0 million. The press release (Exhibit 99.1) contains detailed financial metrics, segment performance analysis, gross margin, operating expenses, and cash position, along with management commentary on business outlook and strategic priorities. This is a standard quarterly earnings release material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:19.181584+00:00","company_name":"ClearPoint Neuro, Inc.","ticker":"CLPT","filing_date":"2026-08-03"}]}